Revvity (RVTY) Income from Continuing Operations (2009 - 2026)
Revvity's (RVTY) quarterly Income from Continuing Operations came in at $53.5 million in Q3 2026, down 3.15% on a YoY basis from $55.2 million in Q3 2025, and up 30.78% quarter-over-quarter from $40.9 million in Q2 2026.
Analysis
Revvity (RVTY) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Revvity (RVTY) has reported Income from Continuing Operations for 18 consecutive years, with $53.5 million the latest figure, recorded in Q3 2026.
- For the quarter ending Q3 2026, Income from Continuing Operations fell 3.15% year-over-year to $53.5 million; the trailing twelve-month figure through Jul 2026 stood at $237.4 million (down 14.82% YoY), and the FY2025 full-year result was $239.9 million, down 15.26% from the prior year.
- Income from Continuing Operations climbed to $53.5 million in Q3 2026 per RVTY's latest filing, from $40.9 million in the prior quarter.
- Across five years, Income from Continuing Operations topped out at $299.7 million in Q1 2022 and bottomed at $24.8 million in Q2 2023.
- Historically, Income from Continuing Operations has averaged $91.4 million across 5 years, with a median of $64.1 million in 2022.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations tumbled 86.5% in 2023, then jumped 187.62% in 2024.
- Over 5 years, Income from Continuing Operations stood at $69.5 million in 2022, then plunged by 53.29% to $32.5 million in 2023, then soared by 172.21% to $88.4 million in 2024, then increased by 8.36% to $95.8 million in 2025, then tumbled by 44.16% to $53.5 million in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered $53.5 million, $40.9 million, and $95.8 million for Q3 2026, Q2 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 241.68 Bn | 237.61 Bn | 8.34 Bn | 1.76 Bn |
| 2 | Danaher | 147.34 Bn | 142.99 Bn | 3.61 Bn | 870.00 Mn |
| 3 | Agilent Technologies | 43.34 Bn | 41.59 Bn | 1.04 Bn | 362.00 Mn |
| 4 | Illumina | 34.58 Bn | 33.41 Bn | 770.00 Mn | 207.00 Mn |
| 5 | Revvity | 16.31 Bn | 15.29 Bn | 416.87 Mn | 53.48 Mn |
| 6 | Bio-Techne | 11.28 Bn | 11.01 Bn | 211.39 Mn | 54.62 Mn |
| 7 | Bio-Rad Laboratories | 10.16 Bn | 8.54 Bn | 345.80 Mn | 371.40 Mn |
| 8 | Repligen | 9.77 Bn | 8.75 Bn | 110.04 Mn | 5.01 Mn |
| 9 | 10x Genomics | 9.45 Bn | 8.90 Bn | 112.50 Mn | -17.93 Mn |
| 10 | Bruker | 9.26 Bn | 9.04 Bn | 416.00 Mn | -65.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 5, 2026 | 53.48 Mn |
| Apr 5, 2026 | 40.89 Mn |
| Dec 28, 2025 | 95.77 Mn |
| Sep 28, 2025 | 47.22 Mn |
| Jun 29, 2025 | 55.22 Mn |
| Mar 30, 2025 | 41.67 Mn |
| Dec 29, 2024 | 88.38 Mn |
| Sep 29, 2024 | 93.39 Mn |
| Jun 30, 2024 | 72.61 Mn |
| Mar 31, 2024 | 28.70 Mn |
| Oct 1, 2023 | 32.47 Mn |
| Jul 2, 2023 | 58.62 Mn |
| Apr 2, 2023 | 24.85 Mn |
| Jan 1, 2023 | 197.82 Mn |
| Oct 2, 2022 | 69.51 Mn |
| Jul 3, 2022 | 161.60 Mn |
| Apr 3, 2022 | 184.07 Mn |
| Jan 2, 2022 | 299.70 Mn |
| Oct 3, 2021 | 107.63 Mn |
| Jul 4, 2021 | 221.24 Mn |